These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 33991850)

  • 1. Meningiomas: A review of general, histopathological, clinical and molecular characteristics.
    Salles D; Santino SF; Malinverni ACM; Stávale JN
    Pathol Res Pract; 2021 Jul; 223():153476. PubMed ID: 33991850
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genetic/molecular alterations of meningiomas and the signaling pathways targeted.
    Domingues P; González-Tablas M; Otero Á; Pascual D; Ruiz L; Miranda D; Sousa P; Gonçalves JM; Lopes MC; Orfao A; Tabernero MD
    Oncotarget; 2015 May; 6(13):10671-88. PubMed ID: 25965831
    [TBL] [Abstract][Full Text] [Related]  

  • 3. TERT promoter mutation is associated with worse prognosis in WHO grade II and III meningiomas.
    Biczok A; Kraus T; Suchorska B; Terpolilli NA; Thorsteinsdottir J; Giese A; Tonn JC; Schichor C
    J Neurooncol; 2018 Sep; 139(3):671-678. PubMed ID: 29808339
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinicopathological variables, immunophenotype, chromosome 1p36 loss and tumour recurrence of 247 meningiomas grade I and II.
    Ruiz J; Martínez A; Hernández S; Zimman H; Ferrer M; Fernández C; Sáez M; López-Asenjo JA; Sanz-Ortega J
    Histol Histopathol; 2010 Mar; 25(3):341-9. PubMed ID: 20054806
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Non-NF2 mutations have a key effect on inhibitory immune checkpoints and tumor pathogenesis in skull base meningiomas.
    Hao S; Huang G; Feng J; Li D; Wang K; Wang L; Wu Z; Wan H; Zhang L; Zhang J
    J Neurooncol; 2019 Aug; 144(1):11-20. PubMed ID: 31177425
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Genetic landscape of meningioma.
    Yuzawa S; Nishihara H; Tanaka S
    Brain Tumor Pathol; 2016 Oct; 33(4):237-247. PubMed ID: 27624470
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular biological determinations of meningioma progression and recurrence.
    Linsler S; Kraemer D; Driess C; Oertel J; Kammers K; Rahnenführer J; Ketter R; Urbschat S
    PLoS One; 2014; 9(4):e94987. PubMed ID: 24722350
    [TBL] [Abstract][Full Text] [Related]  

  • 8. De novo and secondary anaplastic meningiomas: a study of clinical and histomolecular prognostic factors.
    Peyre M; Gauchotte G; Giry M; Froehlich S; Pallud J; Graillon T; Bielle F; Cazals-Hatem D; Varlet P; Figarella-Branger D; Loiseau H; Kalamarides M
    Neuro Oncol; 2018 Jul; 20(8):1113-1121. PubMed ID: 29216385
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Advances in Molecular Classification and Therapeutic Opportunities in Meningiomas.
    Cordova C; Kurz SC
    Curr Oncol Rep; 2020 Jul; 22(8):84. PubMed ID: 32617743
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Natural history of meningioma development in mice reveals: a synergy of Nf2 and p16(Ink4a) mutations.
    Kalamarides M; Stemmer-Rachamimov AO; Takahashi M; Han ZY; Chareyre F; Niwa-Kawakita M; Black PM; Carroll RS; Giovannini M
    Brain Pathol; 2008 Jan; 18(1):62-70. PubMed ID: 17924978
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of 1p and 14q status, MIB-1 labeling index and progesterone receptor immunoexpression in meningiomas: Adjuncts to histopathological grading and predictors of aggressive behavior.
    Kumar S; Kakkar A; Suri V; Kumar A; Bhagat U; Sharma MC; Singh M; Suri A; Sarkar C
    Neurol India; 2014; 62(4):376-82. PubMed ID: 25237942
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Advances in molecular characteristics of pediatric meningiomas].
    Hou XY; Teng LH
    Zhonghua Bing Li Xue Za Zhi; 2024 Oct; 53(10):1065-1069. PubMed ID: 39375095
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expression of the tumor suppressor genes NF2, 4.1B, and TSLC1 in canine meningiomas.
    Dickinson PJ; Surace EI; Cambell M; Higgins RJ; Leutenegger CM; Bollen AW; LeCouteur RA; Gutmann DH
    Vet Pathol; 2009 Sep; 46(5):884-92. PubMed ID: 19429976
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Altered expression of beta-catenin/E-cadherin in meningiomas.
    Brunner EC; Romeike BF; Jung M; Comtesse N; Meese E
    Histopathology; 2006 Aug; 49(2):178-87. PubMed ID: 16879395
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Loss of chromosome 22 and absence of NF2 gene mutation in a case of multiple meningiomas.
    Lomas J; Bello MJ; Alonso ME; Gonzalez-Gomez P; Arjona D; Kusak ME; de Campos JM; Sarasa JL; Rey JA
    Hum Pathol; 2002 Mar; 33(3):375-8. PubMed ID: 11979381
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Diagnostic and prognostic significance of genetic regional heterogeneity in meningiomas.
    Pfisterer WK; Hank NC; Preul MC; Hendricks WP; Pueschel J; Coons SW; Scheck AC
    Neuro Oncol; 2004 Oct; 6(4):290-9. PubMed ID: 15494096
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gene expression profiles of metabolic aggressiveness and tumor recurrence in benign meningioma.
    Serna E; Morales JM; Mata M; Gonzalez-Darder J; San Miguel T; Gil-Benso R; Lopez-Gines C; Cerda-Nicolas M; Monleon D
    PLoS One; 2013; 8(6):e67291. PubMed ID: 23840654
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A genetic strategy to overcome the senescence of primary meningioma cell cultures.
    Baia GS; Slocum AL; Hyer JD; Misra A; Sehati N; VandenBerg SR; Feuerstein BG; Deen DF; McDermott MW; Lal A
    J Neurooncol; 2006 Jun; 78(2):113-21. PubMed ID: 16554968
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differential expression profiling analyses identifies downregulation of 1p, 6q, and 14q genes and overexpression of 6p histone cluster 1 genes as markers of recurrence in meningiomas.
    Pérez-Magán E; Rodríguez de Lope A; Ribalta T; Ruano Y; Campos-Martín Y; Pérez-Bautista G; García JF; García-Claver A; Fiaño C; Hernández-Moneo JL; Mollejo M; Meléndez B
    Neuro Oncol; 2010 Dec; 12(12):1278-90. PubMed ID: 20685720
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expression of c-Myc, neurofibromatosis Type 2, somatostatin receptor 2 and erb-B2 in human meningiomas: relation to grades or histotypes.
    Durand A; Champier J; Jouvet A; Labrousse F; Honnorat J; Guyotat J; Fèvre-Montange M
    Clin Neuropathol; 2008; 27(5):334-45. PubMed ID: 18808065
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.